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Abstract 
Phosphodiesterase (PDE) inhibitors are currently under evaluation as agents that 
may facilitate the improvement of cognitive impairment associated with Alzheimer’s 
disease. Our aim was to determine whether inhibitors of PDEs 4,5 and 9 could 
alleviate the cytotoxic effects of amyloid beta 1–42 (Aβ1-42) via a mechanism 
involving the small heatshock protein HSP20.  We show that inhibition of PDEs 4,5 
and 9 but not 3 induces the phosphorylation of HSP20 which, in turn, increases the 
co-localisation between the chaperone and Aβ1-42 to significantly decrease the toxic 
effect of the peptide. We conclude that inhibition of PDE9 is most effective to combat 
Aβ1-42 cytotoxicity in our cell model. 
 
Introduction 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly and 
numerous studies have shown the amyloid beta (Aβ) peptide to be a key toxic 
component in AD. Involvement of soluble or higher order aggregation species of the 
Aβ peptide, in various intra- or extra-cellular compartments, has been linked to 
neurotoxicity. However, the underlying toxic mechanism triggered by Aβ 
dyshomeostasis promoting the loss of neurons and synaptic failure is still being 
investigated [1]. 
 
One signaling pathway that has been targeted to improve synaptic function is the 
cyclic nucleotide second messenger system. Cyclic AMP (cAMP) [2]and cyclic GMP 
(cGMP) [3]  signaling systems have been shown to have a crucial input into 
regulation of synaptic plasticity, learning and memory. As a result, signalling 
intermediates within these pathways such as phosphodierases [4] and cAMP 
response element binding protein (CREB) [5] have been identified as possible 
therapeutic targets for AD. 
 
The superfamily of phosphodiesterases (PDEs) is an attractive target for modulating 
synaptic plasticity via second messenger signaling as these enzymes provide the 
sole means of cyclic nucleotide degradation. There are 21 different genes that 
encode PDEs and these are separated functionally into 11 families depending on 
characteristics such as cyclic nucleotide specificity and modular structure [6]. Further 
diversity is generated through multiple splice variants existing for a number of PDE 
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families resulting in more than 60 different isoforms of PDE [6]. A number of PDEs 
have been associated with signalling pathways involved in neuropsychiatric 
disorders, particularly PDE4, PDE5 and PDE9, with the latter two more recently 
emerging as novel therapeutic targets for AD [7]. 
 
A topical neuro-protective mechanism that is a consequence of the inhibition of 
PDE4 and PDE5 is the hyper-phosphorylation of the molecular chaperone heatshock 
protein 20 (HSP20) on serine 16 by PKA or PKG [8]. HSP20 is known to associate 
with the pathological hallmarks of AD brains [9] and to physically bind to the  Aβ 
peptide, reducing its toxicity to neurons [10]. Recent data from our lab has shown 
that inhibition of a PDE4 pool directly associated with HSP20 results in its increased 
phosphorylation by PKA [11]which in turn promotes association of the chaperone 
with the self association domain of the Aβ peptide, preventing its oligomerisation [12] 
and reducing its cytotoxicity [13]. We now investigate whether inhibition of PDEs 5 
and 9 result in similar functional consequences with respect to HSP20 
phosphorylation and Aβ toxicity in a cellular model. We report that both inhibition of 
PDE5 and 9 result in a dose dependent phosphorylation of HSP20 on serine 16 that 
promotes greater association of HSP20 with Aβ to decrease Aβ-induced cell death. 
Our results suggest a novel mechanism for PDE inhibitors in the context of AD. 
 
Materials and Methods 
 
Materials 
All chemicals used to conduct this research were of analytical grade and were 
supplied by Sigma-Aldrich, UK, unless otherwise stated. Compounds were typically 
dissolved in dimethyl sulfoxide (DMSO) and added to cells at a concentration no 
greater than 0.1% (v/v). All aqueous solutions were prepared with deionised water 
(dH2O) (Millipore, USA).  Antibodies used in the phosphorylation assays and ICC, α-
pS16-HSP20 Abcam (ab58522), α-Rabbit-HRP Sigma-Aldrich (A6154), α-Rabbit- 
Alexa Fluor® 594 Invitrogen (A-11012). Primary antibody used for PDE9 western 
blotting experiment was supplied by Scottish Biomedicals. 
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RT-PCR 
Approximately 106 SHS5Y cells were harvested, washed in PBS, then snap-frozen 
and stored at -80oC. RNA was prepared using RNeasy column (Qiagen) with on-
column DNAse digestion (Qiagen). 1.5 µg of total RNA (1 µl) was used to synthesise 
20 µl of cDNA using Superscript Vilo cDNA synthesis kit (Invitrogen) with incubation 
times as follows: 25°C, 10 min; 42°C, 120 min; 85°C, 15 min. PDE9A1 intron-
spanning RT-PCR primer pairs were designed to three separate regions of the gene 
sequence (PDE9A1_1, PDE9A1_2, PDE9A1_3), and were re-suspended to a stock 
concentration of 10 µmol/l in nuclease-free water. RT-PCR reactions were performed 
using PDE9A1 primers and GAPDH primers as a positive control at a concentration 
of 200 nmol/l. For the PCR pre-mixed PCR reagent (Thermoscientific) was used with 
the following thermal cycling parameters: 94oC, 2 min then 30 cycles of 94°C, 30 s; 
55°C, 30 s; 72°C, 30 s, followed by 72°C for 20 min. 1 µl of cDNA was used as a 
template in each 20 µl reaction. No template control reactions lacking cDNA were 
included to ensure primer contamination had not occurred. 10 µl of each PCR 
product was resolved on a 1.8%, 0.5x TBE agarose gel. Bands corresponding to the 
predicted molecular weight were obtained for each PCR reaction strongly suggesting 
that PDE9A1 mRNA is expressed in SHS5Y cells. 
 
Preparation of Aβ 
For cell-based assays synthetic Aβ peptides were purchased from rPeptide® 
(Georgia, USA). Aβ1-42 (A-1002) peptides are the recombinant form of the human 
Aβ peptide. Aβ1-42 scrambled peptide (Aβscr) (A-1004) which is a rearranged 
version of the peptide that carries the overall weight and charge of Aβ1-42, was used 
as a control. For ICC experiments fluorescein-tagged Aβ1-42 was purchased from 
Anaspec (ANA23525-05).  Peptides were dissolved in DMSO at a concentration of 
5mg/ml and sonicated in a water bath for 15 minutes. Samples were aliquoted and 
stored at -20°C until required. To create neurotoxic Aβ1-42 derivatives a method 
similar to that described by Lambert et al. (1998) was used, where Aβ1-42 (or 
scrambled) peptides were brought to 100uM in cold PBS and incubated at 4-8°C for 
24 hours. The resulting aggregated peptides were added directly to cell culture 
medium typically at 1:10 dilution (Aβ: media). Samples from each 100µM stock 
added were taken for SDS-PAGE and western blotting analysis. 
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Western blotting 
SDS-PAGE gels were transferred to nitrocellulose membranes using an Invitrogen 
X-Cell apparatus (Invitrogen, Paisley) using Nupage® X-cell Blotting Module and 20x 
NuPage® transfer buffer containing 20% methanol (v/v) in 200ml of dH2O. Proteins 
were transferred at 28V for 1.5 hours and transfer efficacy was established through 
visualisation of molecular weight markers or Ponceau staining. Following transfer 
membranes were incubated in 5% milk solution (w/v) in 1x TBST (20mM Tris-Cl 
pH7.6, 150mM NaCl, 0.1% Tween 20) for 1 hour at room temperature under 
agitating conditions to block non-specific antibodies binding to the membrane. 
Membranes were then incubated in 1% milk solution with the appropriate primary 
antibody added and incubated overnight at 4°C with agitation. The membrane was 
then washed for 3 x 10mins with 1x TBST, and incubated in fresh 1% milk solution 
containing appropriate horse-radish peroxidise (HRP)-conjugated secondary 
antibody for 1-2 hours at room temperature (details of antibodies and dilutions given 
in Table 2.1). After incubation membranes were washed for 3 x 10mins before 
adding Pierce enhanced chemi-luminescence (ECL) Western Blotting Substrate 
(Thermo Scientific, USA). Membranes were incubated in ECL substrate for 1 minute 
before transferring to a light-sensitive cassette. Autoradiographic film was used to 
detect any signals from membranes and films were developed on a Kodak X-omat 
Model 2000 processer. Resulting images were quantified using Quantity One 
(BioRad, USA). 
 
Mammalian Cell Culture 
Cell cultures were examined using a phase contrast inverted microscope (Leitz 
Diavert, Germany) in order to analyse the condition of the cells and to monitor for 
contamination. SH-SY5Y cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) and F12-Ham’s at a 1:1 ratio, media was supplemented with 10% (v/v) 
foetal bovine serum (FBS), 1% (v/v) L-Glutamine, 1% (v/v) Minimum Essential 
Medium – With Non-essential Amino Acids (MEM-NAA) and 1% (v/v) Penicillin-
Streptomycin. Cells were cultured in a humidified, 5% (v/v) CO2, 37°C incubator. 
 
Real-Time Cell Monitoring (xCELLigence) 
The xCELLigence system Real-Time Cell Analyzer RTCA-SP (ACEA Biosciences, 
USA) is an electrical impedance-based real-time cell monitoring system for detection 
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of cellular viability (Fig. 2.2). The recording of cell index values (CI), normalisations 
and the monitoring of Aβ1-42 mediated cytotoxicity was performed using RTCA 
Software 1.2. The RTCA-SP device was calibrated using RTCA Resistor Plate 96 
prior to each experiment and impedance measurements were carried out in 96-well 
E-plates (ACEA). The impedance readout is expressed as arbitrary cell index values. 
The normalisation of cell index arbitrarily sets cell index to 1 at a desired time point, 
which is typically the time of adding compounds. The background impedance caused 
by the media is measured using 100ul in each well prior to seeding of cells and is 
automatically subtracted by the RTCA software using the following equation: CI – (Ζi 
– Ζo)/15 with Ζi as the impedance at any given time point and Ζo being the 
background signal [14]. 
 
HSP20 phosphorylation assays 
SH-SY5Y cells were seeded at a density of 1x106 cell per well onto 6 well plates for 
at least 16 hours prior to treatment with various PDE inhibitors. Compounds were 
diluted in media and added to cells for 0.5, 1, 2, 4 & 6 hours for time course assays 
or incubated for 15 minutes for dose-response assays prior to harvesting using 3T3 
lysis buffer supplemented with protease inhibitor Mini-Complete and phosphatase 
inhibitor phosSTOP (Roche, UK). Phospho-HSP20 levels were analysed using 
standard SDS-PAGE and Western Blotting techniques described previously. 
 
Immunocytochemical staining of SH-SY5Y cells 
SH-SY5Y cells (2 x 105/well) were grown overnight in 6 well plates containing sterile 
coverslips.  Coverslips were sterilised using an ethanol: ether solution (1:1, v/v) and 
air dried for a minimum 30 minutes in a cell culture hood. The following day cells 
were treated with 1µM of fluorescein tagged Aβ1-42 (FAM-Aβ1-42) and incubated for 6 
hours in order to mimic the real-time cell-monitoring assays. SH-SY5Y cells were 
then treated with either rolipram (10µM), sildenafil (1µM), PF-04447943 (1µM), BAY 
73-6691 (1µM) or DMSO only control for 1 hour prior to fixation and immunostaining 
for phospho-HSP20. Cells were fixed on glass coverslips using -20°C methanol 
solution for 5 minutes, then washed twice for 5 minutes in cold PBS with gentle 
agitation. Cells were permeabilised for 20 minutes at room temperature with PBST 
(0.1% Triton-X100 in PBS), then washed for 5 minutes in PBS alone. Nonspecific 
antibody binding sites were blocked by incubating with blocking buffer (0.5% BSA 
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(w/v) in PBS) for either 30 minutes at room temperature, or overnight at 4°C, 
coverslips were then washed twice in PBS for 5 minutes.  The phosphor-HSP20 
primary antibody was diluted to the desired concentrations in blocking buffer, and 
coverslips were incubated with primary antibodies overnight at 4°C. Coverslips were 
then washed three times for 10 minutes in PBS, and incubated with 1:500 dilutions of 
appropriate fluorescently labelled secondary antibodies in a final volume of 500μl per 
coverslip and protected from light. This step took place overnight at 4°C. Following 
secondary antibody incubation, coverslips were washed once in PBS and mounted 
onto glass slides using ProLong Gold antifade reagent with DAPI (4’,6-diamidino-2-
phenylindole) nuclear stain (Molecular Probes) and air dried for a minimum 48 hours 
prior to use. Coverslips were stored at 4°C, protected from light. 
 
 
Results 
 
Expression of PDE4[13] and PDE5[15] had already been confirmed in our cellular 
model SH-SY5Y, although there has been no such confirmation of PDE9. As a 
result, our first priority was to confirm the expression of PDE9 in this cell line. Firstly, 
we used RT-PCR of SH-SY5Y RNA using primer pairs targeted to three distinct 
intron spanning regions of the PDE9A1 gene (Fig. 1A). All three PDE9A primers 
amplified PDE9A cDNA from SH-SY5Y cells.  Secondly, we used a commercially 
available PDE9A antibody to positively identify the enzyme in SH-SY5Y cell lysates. 
We observed PDE9A protein at a number of different molecular weights, suggesting 
that a number of isoforms are expressed (Fig. 1B). 
  
HSP20 phosphorylation at serine 16 is induced by inhibition of PDE4 and PDE5 via 
PKA and PKG activation respectively, however it has not been shown that PDE9 
inhibition can influence such a modification of the chaperone. In light of this, we 
decided to compare HSP20 phosphorylation in SH-SY5Y cells using western blotting 
following pharmacological inhibition of PDE4 using rolipram (Figs. 2A and 3A), PDE5 
with sildenafil  (Figs. 2B and 3B), PDE3 using cilostimide (data not shown) and 
PDE9 utilising two commercially available PDE9 inhibitors, PF-04447943 ( Figs. 2C 
and 3C) and BAY 73-6691 (Figs. 2D and 3D). We lSH-SY5Y cells were treated with 
various concentrations of inhibitors and incubated for 15 minutes (Fig. 2). All of the 
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inhibitors (except cilostimide : data not shown)  promoted dose-dependent increases 
in HSP20 phosphorylation compared with the vehicle control, with 25μM- treated 
cells being statistically significant for all inhibitors except for rolipram (Figs. 2B,C,D). 
Rolipram response was significant over control values when tested at 10μM.(Fig. 
2A). In addition to dose responsiveness, we also evaluated the temporal increase in 
HSP20 phosphorylation over a 6 hour time-course of each inhibitor. As previously 
reported, PDE4 (Fig. 3A) and PDE5 inhibition (Fig. 3B) produced a transient and 
significant increase in HSP20 phosphorylation, peaking at 1 hour.  Interestingly, this 
effect was also observed following treatment with both PDE9 inhibitors. PF-
04447943 treatment caused a significant 4-fold increase (± 0.5, p-value = 0.0001) 
after 1 hour (Fig. 3C) compared to a 9-fold increase (± 4, p-value = 0.03) following 
BAY 73-6691 addition (Fig. 3D) at the same time point.  
 
As we have previously published that increases in HSP20 phosphorylation at serine 
16 triggers a reduction of Aβ peptide toxicity in SH-SY5Y cells [13], we sought to 
discover whether the induction of phospho-HSP20 via pharmacological PDE 
inhibition (Figs 2 and 3) could recreate this neuroprotective effect. Using the 
xCELLigence system for label-free, real-time monitoring of Aβ-induced cytotoxicity 
[13], preliminary growth curves demonstrated that divergence between the Aβ1-42 
and Aβscr growth curves occurred after approximately 6 hours of peptide incubation 
(Suppl fig 1). We concluded that it takes 6 hours for significant quantities of soluble 
Aβ1-42 oligomers to accumulate within the cells to induce SH-SY5Y death, hence we 
added PDE inhibitors 6 hours post Aβ1-42 addition. Treatment with either PF-
04447943 or BAY 73-6691 induced a pronounced effect on neuroblastoma growth 
curves (Fig. 4A), significantly reducing the amount of cell death by Aβ1-42. Inhibition of 
PDE9 provided significant protection against the cytotoxic effects of Aβ1-42 as early 
as 12 hours post treatment (Fig. 4B), reaching a maximum at 48 hours, 158% (± 
24%, p-value = 0.016) for PF-04447943 and 180% (± 35%, p-value = 0.02) for BAY 
73-669. 
When tested in the same manner, the influence of PDE4 and PDE5 inhibition on Aβ1-
42 cytotoxicity was observed to be similar in trend but less pronounced than that 
promoted by PDE9 inhibition (Fig. 5A). The increase in Cell Index relative to Aβ1-42 
control peaked at 48 hour time-points for both rolipram and sildenafil (Fig 5B) with 
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maximum increases of 145% (± 18%, p-value = 0.018) and 144% (± 24%, p-value = 
0.043) respectively (Fig. 5B).  
Given that selective inhibition of PDEs 4, 5 and 9 significantly protected neuronal-like 
SH-SY5Y cells against Aβ1-42 induced cell death, it was important to establish if this 
protective mechanism was mediated to some extent through HSP20. As we have 
shown that phosphorylation of HSP20 increases its association with Aβ1-42 and 
reduces the effective concentration of the chaperone required to inhibit Aβ1-42 
oligomerisation[13], we evaluated the formation of the HSP20-fluorescein Aβ1-42 
tagged complex in cells using immunofluorescence (Fig. 6A). A synthetic FAM-Aβ1-42 
peptide had been shown previously to readily accumulate intracellularly within 
cortical neurons and SH-SY5Y cells at sub-lethal concentrations [16]. This property 
was utilised to quantify co-localisation of phospho-HSP20 and FAM-Aβ1-42  using 
Pearson’s correlation co-efficient (PCC), a statistical tool used to correlate the 
spectral overlap between the red (phosph-HSP20) and green (FAM-Aβ1-42) emission 
channels [17]. We observed a PCC value of 0.327 (± 0.034 SEM) in cells treated 
with vehicle alone indicating little co-localisation (Fig. 6B). All PDE inhibitors tested 
induced significant increases in the co-localisation of FAM-Aβ1-42 with phospho-
Hsp20 (Fig. 6B). Rolipram increased the PCC value to 0.458 (± 0.04, p-value = 
0.034), sildenafil to 0.426 (± 0.03, p-value = 0.049), PF-04447943 to 0.465 (± 0.029, 
p-value = 0.017), and BAY 73-6691 to 0.480 (± 0.069, p-value = 0.022).  This data 
suggests that increases in HSP20 phosphorylation through inhibition of PDE families 
4,5 and 9 serves to promote association of the chaperone with Aβ1-42 attenuating 
aggregation of the peptide and conferring protection against  Aβ1-42  toxicity. 
 
Discussion 
Cyclic nucleotides (cAMP and cGMP) are ubiquitous second messengers that are 
known to relay signals within the brain, influencing synaptic plasticity. In the context 
of AD, increases in cAMP and cGMP triggered by selective inhibition of PDE4 [18], 
PDE5 [19] and PDE9 [20] have been responsible for improved synaptic function and 
memory in AD rodent models. Protective mechanisms promoted by increases in 
cAMP/cGMP include phosphorylation of the transcription factor CREB by PKA/PKG, 
which in turn promotes CREB binding to cAMP response elements on specific DNA 
sequences. This action activates transcription of genes involved in synaptic plasticity 
and neuronal protection, reversing Aβ1-42 induced cognitive deficits (reviewed in [4]).   
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Another protein that can be phosphorylated by PKA/PKG and confers protection in 
AD is the small heatshock protein HSP20.  Phosphorylation of HSP20 is known to 
initiate a variety of cardio-protective effects [8, 21] and promote protection against 
ischemia-reperfusion injury in the brain via a mechanism involving modulation of Bcl-
2 and Bax expression [22]. However, the chaperone’s neuro-protective abilities in AD 
had not previously been linked with its phosphorylation.  Recent work from our 
laboratory has demonstrated that phosphorylation of HSP20 by PKA increases its 
association with the aggregation domain of Aβ1-42, reducing oligomerisation [12] and  
neuronal toxicity of the peptide [13].  We show here that PDE inhibitors, which target 
specifically PDEs 4,5 and 9, induce the phosphorylation of HSP20 in a dose and 
time dependent manner.  It is already known that HSP20 exists in a complex with 
AKAP-Lbc [23] and PDE4D [11] and that dissociation of PDE4 from this signalosome 
results in the phosphorylation of HSP20 , which acts to attenuate hypertrophic  
signaling in a heart failure model [24].  In contrast, the direct association of PDE5 
and 9 with HSP20 has not been investigated, yet our data suggests that the activities 
of these PDEs also influence the probability of HSP20 phosphorylation. Indeed the 
phosphorylation of HSP20 is enhanced in coronary arteries following treatment with 
the PDE5 inhibitor sildenafil [25], but no such data exists for the inhibition of PDE9. 
In light of this, it was unexpected that the PDE9 inhibitors performed best in each 
assay within this study, producing the largest HSP20 phosphorylation, the greatest 
level of protection against Aβ induced cytotoxicity, and the most pronounced 
increase in co-localisation between phospho-HSP20 and FAM-Aβ1-42. Interestingly, 
PDE9 inhibitors have been investigated as modulators of the nitric oxide/guanylate 
cyclase/PKG signalling pathway as a therapeutic strategy [26, 27] and are currently 
under evaluation in clinical trials as cognitive enhancers for AD. We speculate that 
the molecular mechanisms underpinning the neuroprotective capacity of PDE9 
inhibition may involve the enhanced HSP20 phosphorylation, though a recent study 
suggests that certain PDE9 inhibitors may also prevent Aβ1-42 oligomerisation by 
acting as metal ion chelators [28]. 
 
Figure legends 
Figure 1. PDE9 expression in SH-SY5Y cells. (A.) RT-PCR of SH-SY5Y RNA using 
PDE9A1 intron-spanning RT-PCR primer pairs designed to three separate regions of 
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the gene sequence (PDE9A1_1, PDE9A1_2, PDE9A1_3). Negative controls where 
no cDNA template was included are maked (-). (B.) Western blot of SH-SY5Y lysates 
identifying  protein expression of PDE9 isoforms. 
 
Figure 2.  PDE inhibitors increase phosphoHSP20 levels in a time-dependent 
fashion. SH-SY5Y cells were incubated with indicated PDE inhibitors (A) Rolipram 
(10µM), ,  (B) Sildenafil  (1µM),  (C) PF-04447943 (25µM)  and (D) BAY 73-6691 
(25µM) over a time course of 6 hours. Cell lysates were prepared and blotted for 
phospho-HSP20. Levels of phospho-HSP20 were normalised against tubulin and 
increases plotted against control, untreated samples n=3 , errors are SEM..  
Significances were determined using Student’s T-test. *= p,0.05, **=p<0.01, 
***=p,0.001 
 
Figure 3. PDE inhibitors increase phospho-HSP20 levels dose-dependently. 
SH-SY5Y cells were incubated with increasing concentrations of PDE inhibitors (A) 
Rolipram, (B) Sildenafil , (C) PF-04447943 and (D) BAY 73-6691nfor 15 minutes. 
Cell lysates were prepared and blotted for phospho-HSP20. Levels of phospho-
HSP20 were normalised against tubulin and increases plotted against control, 
untreated samples n=3 , errors are SEM..  Significances were determined using 
Student’s T-test. *= p,0.05, **=p<0.01, ***=p,0.001 
 
Figure 4. Inhibition of PDE9 significantly attenuates Aβ1-42 induced cell death. 
(A) Non-invasive evaluation of SH-SY5Y cell viability was undertaken using 
xCELLigence Real-Time Cell Analyzer RTCA-SP following addition of  Aβ1-42 or a 
scrambled version of Aβ1-42  PDE 9 inhibitors were added 6 hours after  Aβ1-42  
addition. (B) Evaluation of changes in normalised Cell Index (n=3) over the Aβ1-42  
time-couse following inhibition of PDE9 with PF-04447943 (left) or BAY 73-6691 
(right). Errors are SEM and significances vs untreated controls determined using 
Student’s T-test. *= p,0.05, **=p<0.01, ***=p,0.001 
 
Figure 5. Inhibition of PDE4 and PDE5 significantly attenuates Aβ1-42 induced cell 
death.(A) Non-invasive evaluation of SH-SY5Y cell viability was undertaken using 
xCELLigence Real-Time Cell Analyzer RTCA-SP following addition of  Aβ1-42 or a 
scrambled version of Aβ1-42  PDE 4 (rolipram) and 5 (sildenafil) inhibitors were added 
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6 hours after  Aβ1-42  addition. (B) Evaluation of changes in normalised Cell Index 
(n=3) over the Aβ1-42  time-couse following inhibition of PDE9 with rolipram (left) or 
sildenafil (right). Errors are SEM and significances vs untreated controls determined 
using Student’s T-test. *= p,0.05, **=p<0.01, ***=p,0.001 
 
Figure 6 . Phosphodiesterase inhibitors increase co-localisation of HSP20 and in 
SH-SY5Y cells. (A)  SH-SY5Y cells were incubated with either 10μM rolipram (Rol), 
1μM sildenafil (Sil), 1μM PF-04447943 (PF) or 1μM BAY73-6691 (BAY) for 15 
minutes prior to methanol fixation and staining with antibodies against phospho-
HSP20 (pS16-HSP20) and the C-terminal domain of APP (APP-CTD) which contains 
the Aβ epitope. Scale bar = 10μm. (B) - Pearson’s Correlation co-efficient (PCC) for 
the colocalisation of phosphor-HSP20 and Aβ were calculatedin cells treated with 
PDE inhibitors. Student’s t-test was used to evaluate changes compared to DMSO 
only controls. (p-values - * < 0.05, ** < 0.01, *** <0.001 Student-T-test, n = 3). 
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